Jones Financial Companies
CGTX icon

Jones Financial Companies’s Cognition Therapeutics CGTX Stock Holding History

Jones Financial Companies’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25.9K Buy
35,481
+5,741
+19% +$6.68K ﹤0.01% 3194
2025
Q4 		$40.1K Buy
29,740
+11,228
+61% +$18.2K ﹤0.01% 2633
2025
Q3 		$24.6K Buy
+18,512
New +$25.2K ﹤0.01% 2686

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Jones Financial Companies's CGTX Position: Q1 2026 in Review

Jones Financial Companies increased its Cognition Therapeutics (CGTX) stake by 19% in Q1 2026, buying an estimated $6.68K and bringing the position to 35,481 shares worth $25.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3194.

Jones Financial Companies first reported a position in CGTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $40.1K in Q4 2025. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • Jones Financial Companies held 35,481 shares of Cognition Therapeutics worth $25.9K as of Q1 2026.
  • Jones Financial Companies bought 5,741 Cognition Therapeutics shares in Q1 2026, an estimated $6.68K.
  • Cognition Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #3194 holding.
  • Jones Financial Companies first reported a position in Cognition Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Jones Financial Companies's Cognition Therapeutics position peaked at $40.1K in Q4 2025.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.